


Dual CAR

Executive summary

An enhanced CD19 CAR T-Cell therapy that by having two targets, CD19 and IgKappa, at the same time can selectively kill a portion of the B-Cells and eradicate the cancer.

“A new therapy that doesn’t eradicate all B-cells like Yescarta and Kymriah can bring great benefits. As a result of saving a proportion of the healthy B-cells, the patient maintains more of the functional immune system and the issues with infections after treatment should be reduced. Another benefit could be a reduced cytokine storm since the number of cells killed and cytokine released will be lowered” KOL: Heidi Glosli, Senior consultant and project leader MD, PhD

Around 70% of the B-Cells in healthy individuals express IgKappa. If the cancer mutation starts in B-Cells expressing IgKappa, all the mutated cancer B-Cells will also express IgKappa. Whether or not the cancer mutation is located in B-Cells expressing IgKappa can easily be analyzed and in around 70% of the cases it is. By targeting B-Cells expressing both CD19 and IgKappa at the same time, this technology has the ability to target the portion of the B-Cells where the cancer is located for the greater part of the B-Cell cancer population.



Business opportunity

Enhancing existing or develop new CD19 CAR cancer therapies by addressing key opinion leaders concerns about toxicity.

Technology/Advantage

Higher specificity without reducing the killing efficacy compared to a standard CD19 CAR.

IPR

Priority filing date: July 9th 2018

Development plans

Further optimization of the technology and verification.

Business offer

Inven2 AS, the TTO at Oslo University Hospital seeks to out-license the IP.

Contact information:

Eirik Løvbakken, Technology Strategy Manager, (+47)92 43 82 14, eirik.lovbakken@inven2.com